Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAR: Treatment of Early Aggressive Rheumatoid Arthritis
NCT00259610Phase 4Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- May 2004
- Primary completion
- Jun 2009
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of etanercept in rheumatoid arthritis (RA) (4 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Disease Activity Score 28-Erythrocyte Sedimentation Rate at 102 weeks. Started May 2004; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00259610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00259610.